Coronary circulatory function in patients with the metabolic syndrome

Journal of Nuclear Medicine

Volumn 52, Issue 9, 2011, Pages 1369-1377

  Di Carli, Marcelo F ^a   Charytan, David ^a   McMahon, Graham T ^a   Ganz, Peter ^a   Dorbala, Sharmila ^a   Schelbert, Heinrich R ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiology (clinical); Coronary blood flow; Metabolic syndrome; Other; PET CT

Indexed keywords

ADENOSINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COLD; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HEART MUSCLE BLOOD FLOW; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ACETATES; ADENOSINE; ADOLESCENT; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL; COHORT STUDIES; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; DATA INTERPRETATION, STATISTICAL; DOUBLE-BLIND METHOD; FEMALE; FRACTIONAL FLOW RESERVE, MYOCARDIAL; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POSITRON-EMISSION TOMOGRAPHY; RISK FACTORS; SULFONIC ACIDS; VASCULAR RESISTANCE; VASODILATOR AGENTS; YOUNG ADULT;

EID: 80052632932     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.082883     Document Type: Article

References (35)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607. (Pubitemid 19004941)
2. Ford E, Giles W, Dietz W. Prevalence of the metabolic syndrome among U.S. adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359. (Pubitemid 34251969)
3. Watarai T, Yamasaki Y, Ikeda M, et al. Insulin resistance contributes to carotid arterial wall thickness in patients with non-insulin-dependent-diabetes mellitus. Endocr J. 1999;46:629-638.
4. DeFronzo RA. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med. 1997;50:191-197. (Pubitemid 27240251)
5. Dayanikli F, Grambow D, Muzik O, Mosca L, Rubenfire M, Schwaiger M. Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. Circulation. 1994;90:808-817. (Pubitemid 24242749)
6. Pitkänen OP, Nuutila P, Raitakari OT, et al. Coronary flow reserve in young men with familial combined hyperlipidemia. Circulation. 1999;99:1678-1684. (Pubitemid 29162479)
7. Di Carli MF, Janisse J, Grunberger G, Ager J. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol. 2003;41:1387-1393. (Pubitemid 36439001)
8. Schindler TH, Cardenas J, Prior JO, et al. Relationship between increasing body weight, insulin resistance, inflammation, adipocytokine leptin, and coronary circulatory function. J Am Coll Cardiol. 2006;47:1188-1195.
9. Hsueh WA, Law R. The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease. Am J Cardiol. 2003;92(4A):3J-9J.
10. Daly CA, Hildebrandt P, Bertrand M, et al. Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial. Heart. 2007;93:1406-1411. (Pubitemid 351480141)
11. Aguilar D, Fisher MR, O'Connor CM, et al. Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease. Am Heart J. 2006;152:298-304. (Pubitemid 44093386)
12. Rewers M, Zaccaro D, D'Agostino R, et al. Insulin sensitivity, insulinemia, and coronary artery disease: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 2004;27:781-787. (Pubitemid 38280550)
13. Forgione MA, Leopold JA, Loscalzo J. Roles of endothelial dysfunction in coronary artery disease. Curr Opin Cardiol. 2000;15:409-415.
14. Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholestrol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
15. Wong ND, Sciammarella MG, Polk D, et al. The metabolic syndrome, diabetes, and subclinical atherosclerosis assessed by coronary calcium. J Am Coll Cardiol. 2003;41:1547-1553. (Pubitemid 36543374)
16. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414-419. (Pubitemid 36935533)
17. Di Carli MF, Bianco-Batlles D, Landa ME, et al. Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. Circulation. 1999;100:813-819. (Pubitemid 29398878)
18. Myers GL, Cooper GR, Winn CL, Smith SJ. The Centers for Disease Control-National Heart, Lung, and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements. Clin Lab Med. 1989;9:105-135. (Pubitemid 19070302)
19. Steiner PM, Freidel J, Breminer WF, Stein E. Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the Lipid Clinic's Methodology. J Clin Chem Clin Biochem. 1981;19:850.
20. Steele BW, Koehler DR, Azar MM, Blaszkowski TP, Kuba K, Dempsey ME. Enzymatic determinations of cholesterol in high-density-lipoprotein fractions prepared by the precipitation technique. Clin Chem. 1976;22:98-101.
21. Friedewald WT, Levy R, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
22. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999;45:2136-2141.
23. Reaven GM. Role of insulin resistance in the pathophysiology of non-insulin dependent diabetes mellitus. Diabetes Metab Rev. 1993;9(suppl 1):5S-12S. (Pubitemid 23345148)
24. Reaven GM. Insulin resistance, compensatory hyperinsulinemia, and coronary heart disease: syndrome X revisited. In: Jefferson LS, Cherrington AD, eds. Handbook of Physiology, Section 7, The Endocrine System, Vol. II, The Endocrine Pancreas and Regulation of Metabolism. New York, NY: Oxford University Press; 2001:1169-1197.
25. Haffner SM. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol. 2003;92(4A):18J-26J.
26. Di Carli M, Czernin J, Hoh CK, et al. Relation among stenosis severity, myocardial blood flow, and flow reserve in patients with coronary artery disease. Circulation. 1995;91:1944-1951.
27. Smits P, Williams SB, Lipson DE, Banitt P, Rongen GA, Creager MA. Endothelial release of nitric oxide contributes to the vasodilator effect of adenosine in humans. Circulation. 1995;92:2135-2141.
28. Nabel EG, Ganz P, Gordon JB, Alexander RW, Selwyn AP. Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. Circulation. 1988;77:43-52. (Pubitemid 18030999)
29. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 2004;89:2595-2600. (Pubitemid 38766337)
30. Dorbala S, Hassan A, Heinonen T, Schelbert HR, Di Carli MF. Coronary vasodilator reserve and Framingham risk scores in subjects at risk for coronary artery disease. J Nucl Cardiol. 2006;13:761-767. (Pubitemid 44890806)
31. Hoang KC, Ghandehari H, Lopez VA, Barboza MG, Wong ND. Global coronary heart disease risk assessment of individuals with the metabolic syndrome in the U.S. Diabetes Care. 2008;31:1405-1409.
32. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299:1561-1573. (Pubitemid 351482795)
33. McMahon GT, Plutzky J, Daher E, Bhattacharyya T, Grunberger G, DiCarli MF. Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes. Diabetes Care. 2005;28:1145-1150. (Pubitemid 40616626)
34. Hamasaki S, Al Suwaidi J, Higano ST, Miyauchi K, Holmes DR Jr, Lerman A. Attenuated coronary flow reserve and vascular remodeling in patients with hypertension and left ventricular hypertrophy. J Am Coll Cardiol. 2000;35:1654-1660. (Pubitemid 30307513)
35. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/ insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. J Clin Invest. 1996;97:2601-2610.